Overview: Monospot TestIntroduction: The Monospot Test detects antibodies to diagnose infectious mononucleosis, causing fever or sore throat. Following 2023 IDSA guidelines, it uses immunoassay for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected Epstein-Barr virus infection.
Other Names: Mono Assay, Heterophile Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: Monospot testing began in the 1960s with EBV research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects antibodies to diagnose infectious mononucleosis, guides treatment, and evaluates patients with fever or sore throat.
Test Parameters: 1. Mononucleosis Antibodies
Pretest Condition: No fasting required. Collect serum. Report history of fever, sore throat, or fatigue.
Specimen: Serum (SST, 2-5 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, sore throat, fatigue, or lymphadenopathy. Include current medications, especially antivirals.
Consent: Written consent required, detailing the tests purpose, infectious mononucleosis implications, and risks of blood collection.
Procedural Considerations: Uses immunoassay to detect heterophile antibodies in serum. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for infectious mononucleosis diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Early infection may yield false negatives.
Clinical Significance: Positive heterophile antibodies confirm infectious mononucleosis, guiding supportive care. Negative results may require EBV-specific testing.
Specialist Consultation: Consult an infectious disease specialist or primary care physician for result interpretation and treatment planning.
Additional Supporting Tests: EBV IgM, EBV IgG, or CBC to confirm infectious mononucleosis diagnosis.
Test Limitations: False negatives in early infection; clinical correlation is needed. Non-EBV causes may mimic results.
References: IDSA EBV Guidelines, 2023; Clinical Infectious Diseases, Cohen JI, 2022.
